The Role of Hypomethylating Agents Prior to Allogeneic Hematopoietic Stem Cells Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome

The Role of Hypomethylating Agents Prior to Allogeneic Hematopoietic Stem Cells Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Background & Aims. The aim of the study was to evaluate the efficacy and safety of azacytidine and decitabine prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia and juvenile myel...

Full description

Saved in:

Bibliographic Details
Main Authors:	VN Ovechkina, SN Bondarenko, EV Morozova, IS Moiseev, AA Osipova, TL Gindina, AI Shakirova, TA Bykova, AD Kulagin, IA Samorodova, EV Karyakina, EA Ukrainchenko, LS Zubarovskaya, BV Afanas’ev
Format:	Article
Language:	Russian
Published:	Practical Medicine Publishing House 2017-07-01
Series:	Клиническая онкогематология
Subjects:	acute myeloid leukemia myelodysplastic syndrome allogeneic hematopoietic stem cell transplantation hypomethylating agents azacitidine decitabine
Online Access:	http://bloodjournal.ru/wp-content/uploads/2017/09/7_1.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Multi-Organ Adverse Reaction to Two Hypomethylating Agents: A Challenge in High-Risk Myelodysplastic Syndrome Treatment
by: Sofia Brites Alves, et al.
Published: (2025-05-01)

Hypomethylating Agents in Oncohematology
by: AD Shirin,, et al.
Published: (2016-10-01)

Acute Myeloblastic Leukemia and Myelodysplastic Syndrome: Azacitidine for Prophylactic and Preventive Purposes after Allogeneic Hematopoietic Stem Cell Transplantation
by: VN Ovechkina, et al.
Published: (2017-01-01)

INFECTIONS IN MYELODYSPLASTIC SYNDROME IN RELATION TO STAGE AND THERAPY
by: Giuseppe Leone, et al.
Published: (2018-07-01)

Myelodysplastic syndromes: therapeutic problems and decisions (review)
by: S. V. Semochkin, et al.
Published: (2014-07-01)

Effect of hypomethylating agents on prognosis in acute myeloid leukemia patients treated with HAG priming: a systematic review and meta-analysis
by: Jun Li, et al.
Published: (2024-12-01)

Treatment of Vietnamese patients diagnosed with myelodysplastic neoplasms: Practical experience in a developing country
by: Quang Hao Nguyen, et al.
Published: (2025-01-01)

New perspectives in the treatment of patients with intermediate-2 and high-risk myelodysplastic syndrome
by: E. V. Morozova, et al.
Published: (2022-11-01)

Exposure-response analyses of venetoclax combined with hypomethylating agents in myelodysplastic syndromes: a retrospective study
by: Ji-Xin Tian, et al.
Published: (2025-07-01)

Selinexor in combination with venetoclax and decitabine in patients with refractory myelodysplastic syndrome previously exposed to hypomethylating agents: three case reports
by: Yunshuo Xiao, et al.
Published: (2024-12-01)

Older Jehovah’s Witnesses with Acute Myeloid Leukemia: Hypomethylating Agents and Venetoclax as a Transfusion-Sparing Approach
by: Aditi Sharma, et al.
Published: (2025-06-01)

Polydatin exerts therapeutic effects on myelodysplastic syndrome by inhibiting the protein expression of oncogenes via hypermethylation in vitro
by: Qingbing Zhou, et al.
Published: (2025-05-01)

Phenotypic and functional changes of NK cells in patients with myelodysplastic syndrome and acute myeloid leukemia treated with hypomethylating drugs
by: D. I. Zhigarev, et al.
Published: (2021-05-01)

Restoration of Autophagy and Apoptosis in Myelodysplastic Syndromes: The Effect of Azacitidine in Disease Pathogenesis
by: Georgia Tsekoura, et al.
Published: (2025-07-01)

Clinical efficacy of azacitidine in the treatment of middle- and high-risk myelodysplastic syndrome in middle-aged and elderly patients: A retrospective study
by: Li Liang, et al.
Published: (2025-04-01)

Enhanced FOXO1 expression as a predictor of decitabine response and prolonged survival in high-risk myelodysplastic syndrome
by: Hong Liu, et al.
Published: (2025-12-01)

Integrating advanced analytical methods to assess epigenetic marks affecting response to hypomethylating agents in higher risk myelodysplastic syndrome
by: Theodoros Nikolopoulos, et al.
Published: (2025-02-01)

Impact of Pre‐Treatment Serum Ferritin on Response and Survival in Myelodysplastic Syndromes Treated With Azacytidine: A Multivariate Analysis
by: Gloria Moreno Carrasco, et al.
Published: (2025-08-01)

A case of atypical prolonged hematologic toxicity with azacitidine in Chronic Myelomonocytic Leukemia (CMML), review of literature and a proposal of management
by: Elena Elli, et al.
Published: (2012-03-01)

Achievements and Challenges in Allogeneic Hematopoietic Stem Cell Transplantation in Cytogenetically Unfavorable Acute Leukemias (Literature Review)
by: NN Mamaev, et al.
Published: (2019-03-01)

Unusual transformation from refractory anemia to chronic myelomonocytic leukemia: a case report.
by: Pasquale Niscola
Published: (2014-08-01)

Hypomethylating agents use in acute myeloid leukemia: A single-center experience
by: Sravan Kumar Bodepudi, et al.
Published: (2020-01-01)

NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
by: Francesco D'Alò, et al.
Published: (2010-08-01)

NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
by: Mariangela Greco, et al.
Published: (2010-05-01)

Hypomethylating therapy mitigates acute allograft rejection in a murine lung transplant model
by: Kristine M. Yarnoff, et al.
Published: (2025-06-01)

Study of myelodysplastic features in patients with myelodysplastic syndromes by multicolor flow cytometry
by: O. Yu. Davydova, et al.
Published: (2019-01-01)

Myelodysplastic Syndrome in a Patient With Cronkhite‐Canada Syndrome
by: Kevin G. Shim, et al.
Published: (2025-08-01)

Long-read detection of transposable element mobilization in the soma of hypomethylated Arabidopsis thaliana individuals
by: Andrea Movilli, et al.
Published: (2025-07-01)

Impact of KIT mutation on efficacy of venetoclax and hypomethylating agents in newly diagnosed acute myeloid leukemia
by: Wenxiu Shu, et al.
Published: (2025-05-01)

THROMBOCYTOPENIA IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES - STILL AN UNSOLVED PROBLEM
by: May Basood, et al.
Published: (2018-07-01)

Efficacy of the combination of venetoclax and hypomethylating agents in the treatment of patients with primary, relapsed and/or refractory acute myeloid leukemia
by: E. V. Usikova, et al.
Published: (2023-01-01)

RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES
by: Julie Schanz, et al.
Published: (2015-04-01)

Combination of hypomethylating agents and inhibitor of BCL-2 in treatment of patients with relapsed acute myeloid leukemia: S.P. Botkin hospital experience
by: M. A. Granatkin, et al.
Published: (2023-03-01)

Myelodysplastic Neoplasms (MDS): Pathogenesis and Therapeutic Prospects
by: Xuefeng Li, et al.
Published: (2025-05-01)

Myelodysplastic syndrome during pregnancy
by: V. I. Medved, et al.
Published: (2022-11-01)

Real‐World Healthcare Resource Utilisation in Patients With Higher‐Risk Myelodysplastic Syndrome During Azacitidine Treatment: A Population‐Based Cohort Study
by: Simone Juline Brommann, et al.
Published: (2025-06-01)

Better Response and Prognosis of Venetoclax Plus Hypomethylating Agents Over Intensive Chemotherapy in Young Adults With Newly Diagnosed ASXL1‐Mutated Acute Myeloid Leukemia
by: Yiming Cai, et al.
Published: (2025-07-01)

Clinical Value of miR-3151 Overexpression in Synergistic Interaction with BAALC Host Gene in Patients with Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
by: AI Shakirova, et al.
Published: (2019-05-01)

Results of Molecular Monitoring in Posttransplant Period by Means of Series Investigation of WT1 Gene Expression in Patients with Acute Myeloid Leukemia
by: YaV Gudozhnikova, et al.
Published: (2018-07-01)

Disseminated tuberculosis masquerading primary myelodysplastic syndrome
by: Syahrul Sazliyana Shaharir, et al.
Published: (2013-03-01)